9 Meters Biopharma (NASDAQ: NMTR) announced significant clinical advancements and financial results for Q2 2020. The company initiated a Phase 1b/2a trial for a long-acting GLP-1 agonist in short bowel syndrome, with top-line data expected in Q1 2021. They amended the primary endpoint for Phase 3 larazotide trial in celiac disease, reducing participants to 525. However, Q2 net loss increased to $44.6 million from $4.5 million YoY, primarily due to merger-related charges, but cash reserves grew from $2.7 million to $13.5 million.
9 Meters Biopharma (NASDAQ:NMTR) initiated a Phase 1b/2a clinical trial for a proprietary GLP-1 agonist for short bowel syndrome, with first dosing in July and expected top-line data by Q1 2021. They amended the primary endpoint in a Phase 3 trial for larazotide in celiac disease, reducing participants from 630 to 525 while keeping 90% statistical power. Despite the pandemic's challenges, clinical sites increased to 115. The company reported a net loss of $44.6 million for Q2 2020, primarily due to merger-related charges, but its cash position improved to $13.5 million.